Showing results (81-90 of 113) with videos related to

Sort By:
Pageof 12
Cancers|January 24, 2019
Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor SurvivalPetros Christopoulos, Steffen Dietz, Martina Kirchner, et al.
International Journal of Cancer|November 18, 2018
Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panelsVolker Endris, Ivo Buchhalter, Michael Allgäuer, et al.
Virchows Archiv : an International Journal of Pathology|June 26, 2021
Status quo of ALK testing in lung cancer: results of an EQA scheme based on in-situ hybridization, immunohistochemistry, and RNA/DNA sequencingPhilipp Jurmeister, Claudia Vollbrecht, Korinna Jöhrens, et al.
Gut|March 23, 2019
RSPO2 gene rearrangement: a powerful driver of β-catenin activation in liver tumoursThomas Longerich, Volker Endris, Olaf Neumann, et al.
Journal of Clinical Medicine|July 2, 2021
Distinct Mutational Profile of Lynch Syndrome Colorectal Cancers Diagnosed under Regular Colonoscopy SurveillanceAysel Ahadova, Pauline Luise Pfuderer, Maarit Ahtiainen, et al.
Ebiomedicine|November 8, 2020
Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNASteffen Dietz, Petros Christopoulos, Zhao Yuan, et al.
The Journal of Molecular Diagnostics : JMD|May 8, 2021
Validation of a Targeted Next-Generation Sequencing Panel for Tumor Mutation Burden Analysis: Results from the Onconetwork Immuno-Oncology ConsortiumFrancesca Fenizia, Ilaria Alborelli, Jose Luis Costa, et al.
Genes, Chromosomes & Cancer|April 23, 2020
NTRK testing: First results of the QuiP-EQA scheme and a comprehensive map of NTRK fusion variants and their diagnostic coverage by targeted RNA-based NGS assaysMartina Kirchner, Julia Glade, Ulrich Lehmann, et al.
British Journal of Cancer|July 23, 2022
Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testingOlaf Neumann, Timothy C Burn, Michael Allgäuer, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2018
PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO studyArndt Vogel, Stefan Kasper, Michael Bitzer, et al.
Pageof 12